Takeda’s Iclusig Looks Set To Become SOC In First-Line Ph+ Acute Lymphoblastic Leukemia

 
• By Alaric DeArment
  
Takeda unveiled data from the Phase III PhALLCON trial of Iclusig in an ASCO monthly plenary session • Source: Shutterstock

More from Clinical Trials

More from R&D